Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents

Mazzotta Valentina 1,2, Cozzi Alessandro 3, Colavita Francesca 4, Rosati Silvia 1, Lalle Eleonora 4, Cimaglia Claudia 5, Paulicelli Jessica 1, Mastrorosa Ilaria 1, Vita Serena 1, Fabeni Lavinia 4, Vergori Alessandra 1, Maffongelli Gaetano 1, Carletti Fabrizio 4, Lanini Simone 1, Caraffa Emanuela 1, Milozzi Eugenia 1, Libertone Raffaella 1, Piselli Pierluca 5, Girardi Enrico 6, Garbuglia AnnaRosa 4, Vaia Francesco 7, Maggi Fabrizio 4, Nicastri Emanuele 1, Antinori Andrea 1, on behalf of INMI COVID-19 Outpatient Treatment Study Group.

1Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy;
2PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University of Rome Tor Vergata, Rome, Italy;
3Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK.
4Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy;
5Clinical Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy;
6Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy;
7General Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy;

Corresponding author
Valentina Mazzotta, MD

e-mail: valentina.mazzotta@inmi.it
Fax: +39 06 55170477

Clinical and Research Infectious Diseases Department
National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Phone: +39 06 55170546
Via Portuense 292, 00149 Roma, Italy

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.28186.

This article is protected by copyright. All rights reserved.
Shortened title
Viral load decrease with early COVID-19 therapies

Keywords: antiviral agents, monoclonal antibodies, virologic efficacy, Omicron variant, BA.1, BA.2.

ABSTRACT (words=212)

Background
The efficacy on the Omicron variant of the approved early coronavirus disease 2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are lacking.

Materials and methods
We assessed potential decrease from day1 to day7 viral load (VL) in nasopharyngeal swabs of outpatients receiving Sotrovimab, Molnupiravir, Remdesivir, or Nirmatrelvir/ritonavir for mild-to-moderate COVID-19 due to sublineages BA.1 or BA.2, and average treatment effect (ATE) by weighted marginal linear regression models.

Results
A total of 521 patients [378 BA.1 (73%), 143 (27%) BA.2] received treatments (Sotrovimab 202, Molnupiravir 117, Nirmatrelvir/ritonavir 84, and Remdesivir 118): median age 66 years, 90% vaccinated, median time from symptoms onset 3 days. Day1 mean viral load was 4.12 log₂ (4.16 for BA.1 and 4.01 for BA.2). The adjusted analysis showed that Nirmatrelvir/ritonavir significantly reduced VL compared to all the other drugs, except vs. Molnupiravir in BA.2. Molnupiravir was superior to Remdesivir in both BA.1 and BA.2, and to Sotrovimab in BA.2. Sotrovimab had better activity than Remdesivir only against BA.1.

Conclusions
Nirmatrelvir/ritonavir showed the greatest antiviral activity against Omicron variant, comparable to Molnupiravir only in the BA.2 subgroup. VL decrease could be a valuable surrogate of drug activity in the context of the high prevalence of vaccinated people and low probability of hospital admission.

MAIN TEXT

Introduction
As of the end of 2021, the Omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its sublineages BA.1 and BA.2, have become the predominant variants responsible for coronavirus disease 2019 (COVID-19) circulating worldwide. The large number of critical mutations in Spike protein of these subvariants raised concerns about the efficacy of therapies for the early phase of COVID-19, particularly of monoclonal antibodies (mAbs). Previously published in vitro data showed that mAbs combination Bamlanivimab/Etezavimab and Casirivimab/Imdevimab showed little neutralizing activity against BA.1 and BA.2; conversely, Sotrovimab retained most of the activity against omicron/BA.1, but was escaped by omicron/BA.2, with a 16 to 37 fold-reduction in neutralizing activity; finally, Tixagevimab/Cilgavimab retained most of the activity against BA.2, but it was not as effective against BA.1. Differently from mAbs, antiviral agents, such as Remdesivir, Molnupiravir, or
Nirmatrelvir/ritonavir, which target the highly conserved protein of SARS-CoV-2, consistently retained in vitro activity against both BA.1 and BA.2 sublineages. Analyses of in vivo data evaluating the clinical efficacy of these agents against the new variant are lacking. Primary endpoint in phase-3 randomized studies in COVID-19 was typically the proportion of participants hospitalized or dead after randomization. Due to the lower risk of severe outcomes following SARS-CoV-2 Omicron infection, and considering the high prevalence of vaccinated people during the Omicron wave, a clinical outcome is not suited to the current scenario.

Viral load reduction from baseline through day 7 was used as the endpoint of phase-2 studies of mAbs and may be a valuable surrogate marker of in vivo neutralizing or antiviral activity.

We assessed the in vivo viral load reduction in nasopharyngeal swab (NPS) collected on day 1 and day 7 from outpatients treated with Sotrovimab, Molnupiravir, Remdesivir, or Nirmatrelvir/ritonavir for mild-to-moderate COVID-19 due to sublineages BA.1 or BA.2.

**Methods**

This analysis uses the data of an observational study on the effectiveness of early treatment for outpatients with mild-to-moderate COVID-19. The study was approved by the Scientific Committee of the Italian Medicine Agency (AIFA) and by the Ethical Committee of the Lazzaro Spallanzani Institute, as National Review Board for the COVID-19 pandemic in Italy (approval number 380/2021).

All consecutive patients presenting from the 21st of December 2021 to the 15th of March 2022 to the National Institute for Infectious Diseases “L. Spallanzani” with a confirmed SARS-CoV-2 Omicron (BA.1 or BA.2) diagnosis and a mild-to-moderate COVID-19, who met AIFA criteria for eligibility for early treatment by mAbs or antiviral agents were enrolled. Treatment allocation was subject to drug availability, time from symptoms onset, and presence of comorbidities as defined by AIFA criteria.

Outpatients visits, with a medical evaluation, vital signs recording, and laboratory tests, were scheduled at baseline (day of treatment, day 1) and after seven days (day 7). Patients were followed-up for the occurrence of clinical events through day 30 after starting treatment through a telephone visit.

SARS-CoV-2 load in NPS was assessed using Abbott Alinity m RealTime System (Abbott Laboratories, Wiesbaden, Germany) on day 1 and day 7, and expressed as log2 of cycle threshold (CT) values. Identification of SARS-CoV-2 variants was performed by Sanger sequencing of the Spike coding gene on samples collected on day 1 using the ABI 3500 analyzer (Applied Biosystem, Waltham, United States). SARS-COV-2 serology was performed by two chemiluminescence microparticle assays (CMIA) detecting anti-Nucleoprotein and anti-Spike/RBD IgG (ARCHITECT SARS-CoV-2 IgG, and ARCHITECT SARS-CoV-2 IgG II Quantitative; Abbott Laboratories, Wiesbaden, Germany, respectively). According to the manufacturer’s instructions, for the two CMIA, Index >1.4 and Binding Antibody Units/mL ≥7.1 are considered positive for anti-N and anti-Spike/RBD IgG, respectively.
Primary endpoint was log2 viral load variation from day 1 to day 7. We adopted the log transformation because the distribution of the viral load change in the raw scale was positively skewed and significantly deviating from the normal distribution. Secondary endpoints were the proportion of negative NPS at day 7 and the proportion of patients who experienced COVID-related clinical failure, defined as hospitalization due to development of severe COVID-19 or death from any cause over days 0-30.

Because of the observed large between-patients variability in day 1 value, we have also performed a sensitivity analysis using the percentage variation at day 7 as an alternative endpoint. This was calculated as the difference between the value at day 7 minus the value at day 1 divided by the value at day 1 (all values in the log2 scale).

Main characteristics of the participants, assessed on day 1, were compared by treatment strategy using Chi-square (categorical variables) and Kruskal-Wallis (continuous variable) tests. We estimated potential outcomes and the average treatment effect (ATE) of treatment on viral load change on day 7. Because we had 4 drugs to compare this led to 6 possible 2-by-2 comparisons in separate parallel trials. We controlled for confounding by modeling the treatment assignment (via inverse probability of weighting) or the outcome (via regression adjustment) or both (doubly robust methods). The latter provides unbiased estimates for the treatment effect even if one of the models is mis-specified. According to our assumptions, we identified the following key confounding factors: calendar month of infusion, immunodeficiency at time of infusion, and duration of symptoms. All analyses were controlled for these factors.

Proportion of participants who experienced the secondary endpoints was shown by treatment group and compared using a Chi-square test. All analyses were stratified by type of Omicron variant detected (BA.1 vs BA.2).

Results

Of 568 participants enrolled, 521 had a viral load measured at day 7: 202 received Sotrovimab, 117 Molnupiravir, 84 Nirmatrelvir/ritonavir, and 118 Remdesivir. Overall, 250 (48%) were female, 469 (90%) were vaccinated and 81 (15%) had negative baseline serology. Median age was 66 years (IQR 55-76) and median time from symptoms onset to day 1 was 3 days (2-4). BA.1 and BA.2 were detected in 378 (73%) and 143 (27%), respectively. A higher proportion of chronic respiratory disease (chi-square, p<0.001), liver disease (p<0.001), and immunodeficiency (p=0.01) was observed on day 1 among participants receiving Sotrovimab. The baseline mean viral load was 4.12 (SD 0.27) log2 CT [4.16 for BA.1 and 4.01 for BA.2]. Detailed characteristics according to treatment groups are reported in Table 1. Linear regression analysis calculating the average treatment effect of therapies when compared to each other in separately emulated parallel trials showed that Nirmatrelvir/ritonavir significantly reduced viral load compared to other drugs both in the BA.1 and BA.2 subgroups. In contrast, there was no difference in activity between Molnupiravir and Nirmatrelvir/ritonavir against BA.2. No evidence for a difference was also found against BA.1 between Sotrovimab and Molnupiravir.

Sotrovimab had better activity than Remdesivir only against BA.1 (Figure 1a and 1b).
Detailed results of potential decrease in viral load and average treatment effect for all possible 2-by-2 treatment comparisons separately for BA.1 and BA.2 are also shown in Supplementary Tables 1 and 2. All variations of SARS-CoV-2 RNA levels from day 1 to day 7 according to treatment groups are reported in Supplementary Figure 1. Results were similar when we used the alternative endpoint of percentage variation at day 7 (Supplementary Table 3).

Proportion of participants with CT≤40 at day 7 was 6.7% (35/521, 31 infected with BA.1 and 4 with BA.2). See details in Table 2.

COVID-19-related hospitalization or death from any cause through day 30 was assessed in 568 patients: 9 patients [7/226 (3.1%) Sotrovimab (5 BA.1) and 2/87 (2.3%) Nirmatrelvir/ritonavir (2 BA.1)] experienced clinical failure.

**Discussion**

Our study showed that considering the reduction of viral load as a marker of antiviral activity in vivo, Nirmatrelvir/ritonavir had the strongest activity in all face-to-face treatment comparisons in patients infected with BA.1 and BA.2, with the only exception of no evidence for a difference versus Molnupiravir for BA.2 infected. Molnupiravir had better activity against Remdesivir in both BA.1 and BA.2, comparable activity against BA.1, and better activity in BA.2 than Sotrovimab. Sotrovimab had better activity than Remdesivir against BA.1 but there was no significant difference between Sotrovimab and Remdesivir for BA.2.

We evaluated the decrease in viral load in the nasopharyngeal swab as a surrogate for drug activity that could reflect the clinical response to treatment. Due to the low rate of hospitalization and death in persons infected with Omicron variants, it has become increasingly difficult to design clinical studies with adequate statistical power. Therefore, in the absence of clinical events, the change in viral load could be a candidate surrogate endpoint for clinical response.

More studies are needed to test whether early viral load decrease is a strong and consistent surrogate or whether it might be subject to what is known as the ‘surrogate paradox’.

Anyway, our results showed concordance of viral load decrease from day 1 to day 7 with known data on early COVID-19 therapies and reflected previously *in vitro* published data: the virologic efficacy of Nirmatrelvir/ritonavir was the counterpart to the high clinical efficacy demonstrated in the registrative trials and real-life data. The lower change in viral load in patients with BA.2 compared with BA.1 during Sotrovimab therapy was also in agreement with the lower neutralizing activity observed *in vitro* for this monoclonal antibody. Likewise, the poor activity on viral load reduction of Remdesivir with both BA.1 and BA.2 subvariants agreed with the data from the Pinetree study. Molnupiravir activity toward both variants, with a better profile on BA.2 also seemed to agree with recent *in vitro* data.

The main limitations of our analysis are the observational nature of the study and the lack of a randomized design, which does not allow to rule out confounding bias. These limitations are partially mitigated by the use of weighted marginal linear regression models and appropriate control of measured confounding factors.
results are however important as, to the best of our knowledge, this is the first analysis to evaluate the \textit{in vivo} efficacy of currently available treatments against the Omicron BA.1 and BA.2 variants.

Even if the evolution of Sars-Cov-2 variants is faster than the generation of data on drug efficacy and the current epidemiological scenario is dominated by new sublineages, data such as ours can still contribute to the classification of the disease, especially in light of the direct correlation with BA.2 of some sublineages (e.g. BA.2.75\textsuperscript{30} in India) and the resulting similar susceptibility. Furthermore, we do not know whether future variants will reoccur with similar mutations to previous ones (as has already happened, for example, with the reappearance in BA.4 and BA.5 of the mutation at position 425, already seen in the Delta variant).

In conclusion, according to our viral load change dynamic model and assumptions, in outpatients with mild-to-moderate COVID-19, Nirmatrelvir/ritonavir appears to be the option with the strongest \textit{in vivo} antiviral activity against the Omicron variant among all other treatment options examined. Only for Molnupiravir and limited to the BA.2 sublineage, the antiviral effect appeared to be comparable to that observed with Nirmatrelvir/ritonavir. Because of the low incidence of hospital admissions in the Omicron era, the emulation of trials with surrogate endpoints such as \textit{in vivo} neutralizing activity can provide useful information for treatment decisions of early COVID-19.
Figure 1. SARS-CoV-2 RNA levels at D1 and D7 in patients treated with Sotrovimab, Molnupiravir, Remdesivir and Nirmatrelvir/ritonavir

Dot-plots showing the comparison of viral loads detected at D1 and D7 and the variation of RNA levels observed between the two time-points by intervention in (A) patients with Omicron BA.1 infection treated with Sotrovimab (n=146), or Molnupiravir (n=99), or Remdesivir (n=84), or Nirmatrelvir/ritonavir (n=49); (B) patients with Omicron BA.2 infection treated with Sotrovimab (n=56), or Molnupiravir (n=18), or Remdesivir (n=34), or Nirmatrelvir/ritonavir (n=35). Viral RNA levels are expressed as log2 CT values. Mean of log2 CT values and SD are shown. Statistical analysis of the comparisons between treatment groups was performed by Kruskal-Wallis test, adjusted with Dunn’s multiple comparisons test. Horizontal dashed line represents the limit of detection (CT: 40.0), values ≥40 are considered negative.

This article is protected by copyright. All rights reserved.
Role of the funding source

This study was supported by funds to the National institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS, Rome (Italy), from Italian Ministry of Health (Programme CCM 2020; Ricerca Corrente - Linea 1 on emerging and re-emerging infections) and from the European Commission - Horizon 2020 (CoNVat, Grant agreement ID 101003544; KRONO, Grant agreement ID 101005075).

Data statement

Anonymized participant data will be made available upon reasonable requests directed to the corresponding author. Proposals will be reviewed and approved by investigator, and collaborators on the basis of scientific merit. After approval of a proposal, data can be shared through a secure online platform after signing a data access agreement.

Author contributions statement

AA and VM conceptualized and designed the study. VM, FC and ACL wrote the first draft of the manuscript and referred to appropriate literature. ACL was also the main responsible person for formal data analysis. AA, ACL, VM, FC, FM and EN conceived, supervised the study and contributed to data interpretation. JP, CC and PP were responsible for data collection and curation. FV, EG, PP, AGR, FM, IM, AV revised the manuscript content, reviewed and edited the manuscript. FC, LF, EL, AGR, FC and FM performed all virological tests. VM, IM, AV, SV, EC, EM, RL, GM and SR enrolled participants. All authors agreed with and approved the final version of the manuscript.

Conflict of Interest Statement

A.A. declares consultancy fees from Gilead Sciences, Merck, GSK, Pfizer, Astra Zeneca, and research institutional grants from Gilead Sciences and the Italian Medicine Agency (AIFA).

EN declares consultancy fees from Gilead Sciences, Eli-lilly, Roche and Sobi.

Acknowledgments

The authors gratefully acknowledge the nurse staff and all the patients and all members of the **INMI COVID-19 Outpatient Treatment Study Group:**

Samir Al-Moghazi, Chiara Agrati, Andrea Antinori, Tommaso Ascoli-Bartoli, Francesco Baldini, Bartolini Barbara, Rita Bellagamba, Giulia Borno, Nazario Bevilacqua, Elisa Biliotti, Giulia Bonfiglio, Licia Bordi, Elena Boschiavo, Marta Camici, Emanuela Caraffa, Rita Casetti, Carlotta Cerva, Stefania Cicalini, Claudia
Cimaglia, Francesca Colavita, Angela Corpolongo, Rita Corso, Alessandro Cozzi Lepri, Gianpiero D’Offizi, Federico De Zottis, Silvia Di Bari, Virginia Di Bari, Francesca Di Bella, Davide Roberto Donno, Angela D’Urso, Lavinia Fabeni, Massimo Francalancia, Marisa Fusto, Roberta Gagliardini, Paola Galli, Francesca Gavaruzzi, Saba Gebremeskel, Letizia Giancola, Giuseppina Giannico, Emanuela Giombini, Enrico Girardi, Giulia Gramigna, Elisabetta Grilli, Cesare Ernesto Maria Gruber, Giuseppina Iannicelli, Daniela Inzeo, Eleonora Lalle, Alessandra Lamonaca, Simone Lanini, Fabio Leotta, Raffaella Libertone, Laura Loiacono, Gaetano Maffongelli, Alessandra Marani, Andrea Mariano, Ilaria Mastro rosa, Giulia Matusali, Stefania Mazzotta, Valentina Mazzotta, Silvia Meschi, Eugenia, Milozzi, Sabrina Minicucci, Annalisa Mondi, Vanessa Mondillo, Emanuele Nicastri, Giovanna Onnelli, Sandrine Ottou, Claudia Palazzolo, Fabrizio Palmieri, Sara Pantanella, Sara Passacantilli, Jessica Paulicelli, Carmela Pinnetti, Pierluca Piselli, Maria Maddalena Plazzi, Alessandra Oliva, Alessia Rianda, Silvia Rosati, Martina Rucea, Alessandra Sacchi, Giuseppe Sberna, Laura Scorzolini, Fabrizio Taglietti, Giuseppina Tarabù, Francesca Trotti, Francesco Vaia, Alessandra Vergori, Serena Vita, Pietro Vittozzi.

Table 1. Main characteristics at enrolment by intervention

| Characteristics                        | Sotrovimab | Molnupiravir | Remdesivir | Nirmatrelvir/ritonavir | p-value | Total |
|----------------------------------------|------------|--------------|------------|------------------------|---------|-------|
| **Gender, n(%)**                        | N= 202     | N= 117       | N= 118     | N= 84                  |         | 521   |
| Female                                 | 105 (52.0%)| 52 (44.4%)   | 52 (44.1%) | 41 (48.8%)             | 0.454   |       |
| **Age, years**                          | 63 (52.75)| 68 (57.75)   | 70 (57.78) | 63 (55.76)             | 0.092   |       |
| Median (IQR)                           | 93 (46.0%) | 65 (55.6%)   | 71 (60.2%) | 36 (42.9%)             | 0.028   | 265   |
| Older than 65, n(%)                    | 93 (46.0%) | 64 (54.7%)   | 71 (60.2%) | 36 (42.9%)             | 0.028   |       |
| Days from symptoms onset to MAb infusion | 3 (2, 5)   | 3 (2, 4)     | 4 (2, 5)   | 3 (2, 4)               |         | 3 (2, 4) |

| **Comorbidities/risk factors, n(%)**    |     |              |            |                        |         |
|----------------------------------------|     |              |            |                        |         |
| Diabetes                               | 28 (13.9%) | 24 (20.5%)   | 23 (19.5%) | 19 (22.6%)             | 0.239   | 94 (18.0%) |
| Obesity (BMI>30)                       | 93 (46.0%) | 64 (54.7%)   | 73 (61.9%) | 53 (63.1%)             | 0.012   | 283 (54.3%) |
| CVD                                    | 31 (15.3%) | 27 (23.1%)   | 24 (20.3%) | 17 (20.2%)             | 0.357   | 269 (19.0%) |
| Chronic respiratory disease            | 22 (10.9%) | 2 (1.7%)     | 1 (0.8%)   | 1 (1.2%)               | <.001   | 25 (5.0%)   |
| Renal impairment                       | 7 (3.5%)   | 1 (0.9%)     | 2 (1.7%)   | 0 (0.0%)               | 0.174   | 10 (1.9%)   |
| Hepatic Disease                        | 61 (30.2%) | 20 (17.1%)   | 21 (17.8%) | 9 (10.7%)              | <.001   | 111 (21.3%) |
| Cancer                                 | 32 (15.8%) | 15 (12.8%)   | 16 (13.6%) | 17 (20.2%)             | 0.485   | 80 (15.4%)   |
| Primary/secondary immunodeficiency     | 52 (25.7%) | 17 (14.5%)   | 18 (15.3%) | 10 (11.9%)             | 0.010   | 97 (18.6%)   |
| Neurologic disease                     | 16 (7.9%)  | 6 (5.1%)     | 3 (2.5%)   | 4 (4.8%)               | 0.229   | 29 (5.6%)    |
| **Vital signs at baseline**            |     |              |            |                        |         |
| SpO2, median (IQR)                     | 98 (97, 99)| 98 (97, 99)  | 98 (97, 98)| 98 (97, 99)            | 0.173   | 98 (97, 99) |
| Fever (>37.5°C, n(%)                   | 8 (4.2%)   | 0 (0.0%)     | 2 (1.8%)   | 0 (0.0%)               | 0.036   | 10 (2.0%)   |
| BMI, median (IQR)                      | 24.65 (22.20, 28.57)| 25.26 (23.23, 29.40)| 26.19 (23.23, 29.02)| 26.06 (23.44, 29.48) | 0.093   | 25.31 (22.99, 29.05) |

| **Laboratory values, median (IQR)**    |     |              |            |                        |         |
|----------------------------------------|     |              |            |                        |         |
| Ferritin, ng/ml                        | 99.00 (39.00, 181.0) | 89.00 (48.00, 173.0) | 84.00 (44.00, 155.0)  | 94.00 (55.00, 145.0) | 0.885   | 91.00 (47.00, 171.0) |
| C-reactive protein, mg/dl              | 0.95 (0.32, 2.48)  | 0.93 (0.29, 1.91) | 0.88 (0.34, 1.67)     | 0.99 (0.37, 1.98)    | 0.793   | 0.93 (0.32, 2.09)   |
| Lymphocytes, /μL                       | 1270 (870.0, 1670) | 1460 (1145, 1700) | 1470 (1100, 1500)     | 1500 (1120, 1940)    | <.001   | 1400 (1010, 1400)   |
Table 2. Proportion of participants with undetectable Sars-CoV-2 in nasopharyngeal swab collected at day 7 (defined as cycle threshold, CT≤40) by intervention.

| Regimen started | Sotrovimab n (%) | Molnupiravir n (%) | Remdesivir n (%) | Nirmatrelvir/ritonavir n (%) | Total n (%) | p-value* |
|-----------------|------------------|--------------------|------------------|-----------------------------|-------------|---------|
| **Baseline CT** |
| Mean (SD)       | 17.57 ± 3.39     | 17.75 ± 3.72       | 17.99 ± 3.31     | 17.23 ± 3.49                | 17.65 ± 3.46|         |
| log2 scale Mean (SD) | 4.11 ± 0.27 | 4.12 ± 0.28 | 4.15 ± 0.26 | 4.08 ± 0.28 | 4.12 ± 0.27 |
| **Less than 25, n(%)** | 195 (96.5%)  | 114 (94.7%)        | 113 (95.8%)      | 81 (96.4%)                  | 358 (96.5%)|         |
| **MASS score, median (IQR)** | 3 (0, 5)       | 3 (2, 5)           | 3 (2, 5)         | 3 (1, 4)                    | 3 (1, 5)   |         |
| **Baseline symptoms score, median (IQR)** | 11 (6, 14) | 11 (7, 16) | 8 (4, 15) | 12 (8, 16) | 0.172 |         |

| Regimen started | Omicron (BA.1 + BA.2) | Day7 CT > 40 | 0.0001 | 0.0010 | 0.0010 | 0.0031 | 0.0001 |
|-----------------|------------------------|--------------|--------|--------|--------|--------|--------|
| **Sotrovimab** | 8 (3.96)               | 9 (7.69)     | 7 (5.93) | 11 (13.10) | 35 (6.72) | 0.0001 |
| **Molnupiravir** | 7 (5.93)               | 108 (92.31)  | 111 (94.07) | 73 (86.90) | 486 (93.28) |     |
| **Remdesivir** | 7 (5.93)               | 111 (94.07)  | 73 (86.90) | 486 (93.28) |         |     |
| **Nirmatrelvir/ritonavir** | 11 (13.10) | 73 (86.90) | 486 (93.28) |         |     |
| **Total n (%)** | 35 (6.72)           | 486 (93.28)  | 93 (97.20) |         |     |
| **Omicron BA.1** | Day7 CT > 40 | 8 (5.48)     | 9 (9.09) | 7 (8.33) | 7 (14.29) | 31 (8.20) | 0.0010 |
| **Day7 CT ≤ 40** | 138 (94.52) | 90 (90.91)   | 77 (91.67) | 42 (85.71) | 347 (91.80) |     |
| **Omicron BA.2** | Day7 CT > 40 | 0 (0)         | 0 (0)     | 0 (0)     | 4 (11.43)  | 4 (2.80)  | 0.0031 |
| **Day7 CT ≤ 40** | 56 (100)     | 18 (100)     | 34 (100)  | 31 (88.57) | 139 (97.20) |     |

*p-value* Fisher's exact test

References
1. CoVariants. Overview of variants/mutations. April 4, 2022 (https://covariants.org/per-variant).
2. Iketani, S., Liu, L., Guo, Y. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553–556 (2022). https://doi.org/10.1038/s41586-022-04594-4
3. Dejnirattisai W, Huo J, Zhou, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell (2022), DOI: https://doi.org/10.1016/j.cell.2021.12.046
4. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Nature https://doi.org/10.1038/s41586-021-03796-6 (2021).
5. Planas D, Saunders N, Maes P. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022). https://doi.org/10.1038/s41586-021-04389-z
6. Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022). https://doi.org/10.1038/s41586-021-04386-2
7. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 2022; 604, 553-556. doi: 10.1038/s41586-022-04594-4.
8. Bruehl T, Hadjadj J, Maes P, et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med 2022. doi:10.1038/s41591-022-01792-5.
9. Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res 2022; 198,105252. doi: 10.1016/j.antiviral.2022.105252.
10. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med 2022; 386, 995-998. DOI: 10.1056/NEJMec2119407.
11. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMoa2201933. Epub 2022 Mar 9. PMID: 35263535; PMCID: PMC8929374.
12. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, Perry R, Boscia J, Heller B, Morris J, Crystal C, Igbinadolor A, Huhn G, Cardona J, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallawaard NL, Sabo J, Patel DR, Dabora MC, Klekotka P, Shen L, Skovronsky DM; BLAZE-1 Investigators. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med. 2021 Oct 7;385(15):1382-1392. doi: 10.1056/NEJMoa2102685. Epub 2021 Jul 14. PMID: 34260849; PMCID: PMC8314785.
13. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Aclouque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J
This article is protected by copyright. All rights reserved.
24. Meschi S, Matusali G, Colavita F, Lapa D, Bordi L, Puro V, Leoni BD, Galli C, Capobianchi MR, Castillettii C; INMI Covid-19 laboratory and investigation team. Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine. Clin Chem Lab Med. 2021 Sep 8;59(12):2010-2018. doi: 10.1515/cclm-2021-0700. PMID: 34492749.

27. Vanderweele TJ. Surrogate measures and consistent surrogates. Biometrics. 2013 Sep;69(3):561-9. doi: 10.1111/biom.12071. PMID: 24073861; PMCID: PMC4221255.

28. Wu Z, He P, Geng Z. Sufficient conditions for concluding surrogacy based on observed data. Stat Med. 2011 Aug 30;30(19):2422-34. doi: 10.1002/sim.4273. Epub 2011 May 17. PMID: 21590703.

29. Ronen Arbel, Yael Wolff Sagy, Moshe Hoshen et al. Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge, 01 June 2022, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-1705061/v1]

30. Cao Y, Song W, Wang L, Liu P, Yue C, Jian F, Yu Y, Yisimayi A, Wang P, Wang P, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Jin R, Wang Y, Xie XS, Wang X. Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75. Preprint version available at bioRxiv 2022.07.18.500332; doi: https://doi.org/10.1101/2022.07.18.500332